Black Diamond Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark A. Velleca
- Full Time Employees
- 24
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Main Street Cambridge MA United States of America 02142
- IPO Date
- Jan 31, 2020
- CIK
- 0001701541
- Website
- blackdiamondtherapeutics.com
- Similar Companies
- Business
- Black Diamond Therapeutics, Inc. (BDTX), a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies targeting families of oncogenic mutations in patients with genetically defined solid tumors; its proprietary MAP (Mutation-Allostery-Pharmacology) drug discovery engine enables the design of brain-penetrant small-molecule inhibitors that address intrinsic and acquired resistance while minimizing wild-type toxicities. The company's lead product candidate, BDTX-1535 (silevertinib), a fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, advances in a Phase 2 trial for EGFR-mutant non-small cell lung cancer (NSCLC), including first-line patients where it demonstrates a 60% objective response rate and 86% central nervous system response rate, and a Phase 1 trial for glioblastoma with a randomized Phase 2 trial planned for 2026; BDTX-4933, a RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors, progresses in Phase 1 development; BDTX-4876, a selective FGFR2/3 MasterKey inhibitor, remains in preclinical stages. Founded in 2014 and headquartered at One Main Street, 14th Floor, Cambridge, Massachusetts, the company operates primarily in the United States with a global focus on precision oncology for patients with brain-penetrant needs in CNS disease and resistant cancers. In March 2025, Black Diamond entered a global licensing agreement with Servier for BDTX-4933, securing a $70 million upfront payment and up to $710 million in milestones to fund operations into Q4 2026; the deal reported as a $56.5 million net income in Q1 2025, reversing prior losses, while recent pipeline prioritization advances key catalysts like Phase 2 NSCLC data disclosures.
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
What's Going On With Black Diamond Therapeutics Stock Tuesday?
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
BDTX Shares Gain 11% in a Week: Here's What You Should Know
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026
Black Diamond Stock: Weighing Catalysts vs. Concentration
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside